Rosuvastatin

Rosuvastatin has been studied in 180 papers since 2007: 38 trials and 52 observational studies in people, 29 in animals, 8 in cells, 32 reviews; 111 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Effect of High-Intensity Statin Therapy on Coronary Plaque Composition Assessed by Machine Learning-Based Optical Coherence Tomography Analysis”.

InterventionStatinsApproved 2003

180 papers study it21 more mention it169 findingsUpdated

PubChemChEBI

36 new papers in 30 daysSee all 200 papers on rosuvastatin

At a glance

A human trial reports less cognitive impairment with low-dose rosuvastatin versus placebo, and independent labs report reduced inflammation in humans; apoptosis results differ across cells and animals. Some registered trials concern aging; across all uses, most ended over a year ago without posted results or linked papers. Some trials are developer-sponsored, and some authors work at AstraZeneca.

169 findings in 81 papers from 2007 to 2026, 17 of them since April 2026

Independent labs found the same change in cells, mice and people. 65 independent labs in 23 countries; 492 trials, 88 about aging, 283 with no results posted.

“-0.54 (95% CI -1.88 to 0.80) for rosuvastatin compared with placebo”
Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 studyNeurology2019doi:10.1212/wnl.0000000000007174

6 of its findings point the other way.

Cells, mice and humans: replicated by independent labs. Worms or flies: nothing yet.
  • 65 independent labs in 23 countries
  • 6 findings against
  • 492 trials, 88 about aging, 283 with no results posted
  • Funders: National Natural Science Foundation of China and others
  • 4 of 164 findings with company ties
  • 125 of 492 trials sponsored by its developers
  • Human trial38
  • Humans52
  • Animals29
  • Cells8
  • In silico3

20 studies gave rosuvastatin to people and measured what changed.

What changedDesignPeopleSource

down: Decreases endocan

down: Decreases endoglin

Treated cohortmedian 12 (IQR 8–12) weeks128 peoplewomenmedian age 60 years (IQR 56–64 years)Postmenopausal women aged up to 70 yearsBiomedicines, Aug 27, 2026

no change: Has no effect on psoriasis area and severity indexChange from baseline: -2.34 (SD 2.81) versus -1.93 (SD 3.33); P = 0.38

no change: Has no effect on dermatology life quality index

Trial12 weeks24 peoplePlaque psoriasis with cardiovascular risk; add-on versus standard therapyPerspectives in clinical research, Jan 17, 2026

down: Decreases cardiac biomarkers

up: Improves global left ventricular strain

down: Lowers the risk of atrial fibrillation8% versus 24%; p = 0.001

Trial8, 24, and 48 hours after surgeryChronic statin users undergoing off-pump coronary artery bypass grafting; loading versus no loadingCureus, Jan 12, 2026

up: Improves LDL-C target attainment rate81.1% vs. 67.6%, p = 0.02

Trial16 weeks145 peopleWomenPostmenopausal womenBiomedicines, Jan 6, 2026

up: Increases left ventricular ejection fraction

Randomized trial8 weeks105 people≥60 yearsSTEMI patients aged ≥60 yearsFrontiers in cardiovascular medicine, Aug 22, 2025

What did studies of rosuvastatin find?

97

Studies of rosuvastatin measured 97 outcomes, among them inflammation, apoptosis and mortality.

Inflammation

downin humans3downin mice1downin O. cuniculus1downin rats1

6 studies
  1. Rosuvastatin decreases inflammation in humans.

    “After treatment, serum levels of hs-CRP, IL-6, TNF-α, and ICAM-1 decreased in both groups (P < 0.05), with the reductions being more pronounced in the intensive group compared to the control group (P < 0.05).”

    Human trial8 weeksn = 105

    Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI

    Frontiers in cardiovascular medicine

  2. Rosuvastatin decreases inflammation in humans (STEMI undergoing PCI) (P < 0.05).

    “intensive group showed significantly reduced serum inflammatory levels compared to the control group, including C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and intercellular adhesion molecule-1”

    Human trialSTEMI undergoing PCIheart20 mg/day vs 10 mg/day8 weeksn = 100

    Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI

    Frontiers in cardiovascular medicine

  3. Rosuvastatin decreases inflammation in humans (coronary heart disease).

    “lower levels of hs-CRP, TNF-α, BNP and NT-proBNP were observed in the observation group than in the control group at T3 and T4 (P<0.05).”

    Human trialcoronary heart disease20 daysn = 100

    Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function and inflammatory factor levels in elderly patients with coronary heart disease

    American journal of translational research

  4. Rosuvastatin decreases inflammation in humans (unstable angina pectoris).

    “hs-CRP and IL-6 levels decreased in both groups after treatment and were lower in group B than in group A (P<0.05).”

    Human trialunstable angina pectorisoral10 mg/day vs 5 mg/dayn = 106

    Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris

    American journal of translational research

  5. Rosuvastatin decreases inflammation in rats (burn wound) (P < 0.01).

    “Histopathology revealed a statistically significant reduction in inflammatory infiltration, coagulative necrosis, and microhemorrhage (P < 0.01).”

    Animalsburn woundcreamskinmalesn = 90

    Experimental beneficial effect of rosuvastatin on burn wound healing in a rat model

    World journal of experimental medicine

  6. Rosuvastatin decreases inflammation in mice (sepsis).

    “it ameliorated lung inflammation”

    Animalssepsislung

    The beneficial effects of Rosuvastatin in inhibiting inflammation in sepsis

    Aging

  7. Rosuvastatin decreases inflammation in O. cuniculus (compared with fluvastatin, under high-cholesterol diet) (greater reduction than fluvastatin).

    “Nevertheless, rosuvastatin administration resulted in a greater reduction in MYD88, NF-kB, chemokines”

    Animalscompared with fluvastatin, under high-cholesterol dietmyocardium

    Myocardial Expression of Pluripotency, Longevity, and Proinflammatory Genes in the Context of Hypercholesterolemia and Statin Treatment

    Journal of clinical medicine

More on Inflammation

Apoptosis

downin rats2downin cells1upin human cells1upin mice1+1

6 studies
  1. Rosuvastatin decreases apoptosis in cells (ox-LDL-induced).

    “rosuvastatin protected against ox-LDL-induced endothelial apoptosis”

    Cellsox-LDL-inducedendothelial cells

    Rosuvastatin protects against oxLDL-induced endothelial cell oxidative stress and attenuates atherosclerotic plaque formation in ApoE-/- mice through the NF-κB pathway

    PloS one

  2. Rosuvastatin induces apoptosis in mice (adulthood).

    “an increased ovarian follicular atresia, as confirmed by increased cleaved caspase-9 and caspase-3 immunostaining in the granulosa cells of antral follicles, in the rosuvastatin-treated females”

    Animalsadulthoodgavageovaryfemales

    Rosuvastatin exposure during adulthood increases ovarian follicular atresia and reduces reproductive performance in female mice

    Toxicology letters

  3. Rosuvastatin induces apoptosis in lipopolysaccharide-stimulated HT-29 and Caco-2 cells.

    “Both pathways converge upon activation of executioner caspase-3 and an increase in Annexin V-defined apoptotic fractions”

    Cellsin lipopolysaccharide-stimulated HT-29 and Caco-2 cells

    Pharmacologic Modulation of the PAR-2-ERK Axis by Statins Converts Inflammatory Survival Signalling into Apoptosis in Colorectal Cancer Cells

    International journal of molecular sciences

  4. Rosuvastatin decreases apoptosis in rat cells (mechanical stretch; cultures from hypertensive rats).

    “Rosuvastatin can reduce vascular remodeling and allostatic overload during hypertension by decreasing MS-associated apoptosis/fibrosis in mesenteric VSMC”

    Cellsmechanical stretch; cultures from hypertensive ratsmesenteric vascular smooth muscle cell10−5 mol/L

    Rosuvastatin Reduces Allostatic Overload due to Mechanical Strain: A New Finding on Vascular Remodeling Linked to Hypertension in Spontaneously Hypertensive Rats

    Current hypertension reviews

  5. Rosuvastatin decreases apoptosis in rats after gamma irradiation.

    “the suppression of intrinsic apoptosis triggered by radiation, as shown by decreased cleaved caspase-3 expression”

    Animalsafter gamma irradiationkidney10 mg/kg i.p.

    Role of mitophagy in acute and fractionated gamma radiation-induced nephropathy in rats: insight into molecular biology and repurposing of rosuvastatin

    Naunyn-Schmiedeberg's archives of pharmacology

  6. Rosuvastatin decreases apoptosis in spontaneously hypertensive rats.

    “Rosuvastatin can inhibit myocardial apoptosis in hypertensive rats through up-regulating SIRT1 and down-regulating NF-κB.”

    Animalsin spontaneously hypertensive ratsmyocardium

    Effect of Rosuvastatin on Myocardial Apoptosis in HypertensiveRats Through SIRT1/NF-κB Signaling Pathway

    Cellular and molecular biology (Noisy-le-Grand, France)

More on Apoptosis

Mortality

no changein humans2downin humans1downin mice1HR 0.96

4 studies
  1. Rosuvastatin showed no clear effect on mortality in humans (elective operations under general anesthesia) (6.1% vs 8.7%, OR = 0.67, 95%CI: 0.39-1.2, P = 0.147).

    “No significant difference in 30-d all-cause mortality (6.1% vs 8.7%, OR = 0.67, 95%CI: 0.39-1.2, P = 0.147) was observed between the two groups.”

    Human trialelective operations under general anesthesia40 mg/d30-dn = 821

    Effects of perioperative rosuvastatin on postoperative delirium in elderly patients: A randomized, double-blind, and placebo-controlled trial

    World journal of clinical cases

  2. Rosuvastatin decreases mortality in humans (hypertension) (all p < 0.05).

    “cardiovascular death, and all-cause death were significantly lower in the rosuvastatin group than the placebo group (all p < 0.05).”

    Human trialhypertension83.5 monthsn = 1,244

    Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults

    Frontiers in cardiovascular medicine

  3. Rosuvastatin was not clearly linked with mortality in humans (primary biliary cholangitis) (HR, 0.960 [95% CI, 0.710–1.296]; p = 0.788).

    “High-intensity hydrophilic and high-intensity lipophilic statins did not differ in all-cause mortality (HR, 0.960 [95% CI, 0.710–1.296]; p = 0.788)”

    Humansprimary biliary cholangitis≥ 20 mg5-year

    High-intensity hydrophilic versus lipophilic statins in patients with primary biliary cholangitis: a multi-institutional analysis

    BMC gastroenterology

  4. Rosuvastatin decreases mortality in mice (sepsis).

    “the administration of Rosuvastatin reduced the mortality of sepsis mice”

    Animalssepsis

    The beneficial effects of Rosuvastatin in inhibiting inflammation in sepsis

    Aging

LDL cholesterol

downin humans3

3 studies
  1. Rosuvastatin decreases LDL cholesterol in humans.

    “After 6 weeks of using high-dose rosuvastatin, the levels of total cholesterol and LDL were significantly decreased (P value = 0.001).”

    Human trial6 weeksn = 110

    Assessing the effect of high-dose rosuvastatin in elderly patients over 75 with acute coronary syndrome

    BMC cardiovascular disorders

  2. Rosuvastatin decreases LDL cholesterol in humans (acute coronary syndrome) (72.6 ± 17.5 to 50.9 ± 18.9, p = 0.001).

    “there was a significant reduction in total cholesterol (136.2 ± 24.3 to 115.5 ± 24.0, p = 0.001) and LDL levels”

    Human trialacute coronary syndrome40 mg6 weeksn = 110

    Assessing the effect of high-dose rosuvastatin in elderly patients over 75 with acute coronary syndrome

    BMC cardiovascular disorders

  3. Rosuvastatin decreases LDL cholesterol in humans (coronary heart disease).

    “the observation group obtained lower TC and LDL-C levels than the control group at T3 and T4 (P<0.05).”

    Human trialcoronary heart disease20 daysn = 100

    Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function and inflammatory factor levels in elderly patients with coronary heart disease

    American journal of translational research

  4. Rosuvastatin decreases LDL cholesterol in humans (Highest-ranked regimen for LDL cholesterol reduction in the network meta-analysis) (P-score 0.9906).

    “For LDL-C reduction, rosuvastatin 10 mg ranked highest (P-score 0.9906)”

    ReviewHighest-ranked regimen for LDL cholesterol reduction in the network meta-analysis10 mg

    Dose-Dependent Lipid Effects and Safety of Pitavastatin versus Other Statins in Dyslipidemia: A Systematic Review and Network Meta-Analysis

    AHA Scientific Sessions 2026 abstract

More on LDL cholesterol

HDL cholesterol

upin humans3

3 studies
  1. Rosuvastatin increases HDL cholesterol in humans (38.3 ± 7.1 to 47.2 ± 7.4).

    “Also, the level of HDL was 38.3 ± 7.1 before treatment and remarkably increased to 47.2 ± 7.4 after treatment (P value = 0.001).”

    Human trial6 weeksn = 110

    Assessing the effect of high-dose rosuvastatin in elderly patients over 75 with acute coronary syndrome

    BMC cardiovascular disorders

  2. Rosuvastatin increases HDL cholesterol in humans (acute coronary syndrome) (38.3 ± 7.1 to 47.2 ± 7.4, p = 0.001).

    “accompanied by a notable increase in HDL levels (38.3 ± 7.1 to 47.2 ± 7.4, p = 0.001)”

    Human trialacute coronary syndrome40 mg6 weeksn = 110

    Assessing the effect of high-dose rosuvastatin in elderly patients over 75 with acute coronary syndrome

    BMC cardiovascular disorders

  3. Rosuvastatin increases HDL cholesterol in humans (compared with atorvastatin, with exercise) (+12 ± 9 mg/dL (+30%) vs +5 ± 5 mg/dL (+13%), p=0.014).

    “Rosuvastatin significantly increased HDL-C (rosuvastatin, +12 ± 9 mg/dL [+30%], atorvastatin, +5 ± 5 mg/dL [+13%], p=0.014)”

    Human trialcompared with atorvastatin, with exercise20 weeks

    Rosuvastatin combined with regular exercise preserves coenzyme Q10 levels associated with a significant increase in high-density lipoprotein cholesterol in patients with coronary artery disease

    Atherosclerosis

  4. Rosuvastatin increases HDL cholesterol in humans (Acute coronary syndrome; compared with atorvastatin) (WMD -1.15; 95% CI -1.99 to -0.32).

    “rosuvastatin may provide greater short-term reductions in CRP and modest increases in HDL-C compared with atorvastatin”

    ReviewAcute coronary syndrome; compared with atorvastatin≤1 month

    Effect of Atorvastatin and Rosuvastatin on Lipid Parameters and Inflammatory Biomarkers in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

    Cardiology in review

More on HDL cholesterol

C-reactive protein

downin humans3

3 studies
  1. Rosuvastatin decreases C-reactive protein in humans (Compared with atorvastatin after excluding one outlying study) (MD −0.16 mg/L; 95% CI −0.28 to −0.03; p = 0.01).

    “rosuvastatin demonstrated a greater CRP reduction (MD –0.16 mg/L; 95% CI –0.28 to –0.03; p = 0.01)”

    ReviewCompared with atorvastatin after excluding one outlying study

    Comparative Effects of Atorvastatin and Rosuvastatin on Randomized Head-to-Head Trials: A Systematic Review and Meta-Analysis of Inflammatory Biomarker Changes

    AHA Scientific Sessions 2026 abstract

  2. Rosuvastatin decreases C-reactive protein in humans (Acute coronary syndrome; compared with atorvastatin) (WMD 4.08; 95% CI 1.53–6.63).

    “rosuvastatin may provide greater short-term reductions in CRP and modest increases in HDL-C compared with atorvastatin”

    ReviewAcute coronary syndrome; compared with atorvastatin≤1 month

    Effect of Atorvastatin and Rosuvastatin on Lipid Parameters and Inflammatory Biomarkers in Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis

    Cardiology in review

  3. Rosuvastatin decreases C-reactive protein in humans after excluding one outlier (MD: -0.16 mg/L).

    “rosuvastatin showed a greater reduction (MD: - 0.16 mg/L; 95% CI: - 0.28 to - 0.03; p = 0.01; I2 = 63%).”

    Reviewafter excluding one outliern = 6,148

    Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials

    BMC cardiovascular disorders

More on C-reactive protein

SIRT1

upin rats2upin humans1

3 studies
  1. Rosuvastatin increases SIRT1 in humans.

    “Quantitative gene expression analysis showed that SIRT1 significantly upregulated in patients with MS after 3 months of statin therapy (P < 0.001) (see panel A of the ).”

    Human trial3 monthsn = 25

    Evaluation of Rosuvastatin Therapy on SIRT1 Gene Expression in Patients with Multiple Sclerosis: An Uncontrolled Clinical Trial

    Current therapeutic research, clinical and experimental

  2. Rosuvastatin activates SIRT1 in rats after gamma irradiation.

    “ROSU activated SIRT1 and promoted FOXO3a deacetylation”

    Animalsafter gamma irradiationkidney10 mg/kg i.p.

    Role of mitophagy in acute and fractionated gamma radiation-induced nephropathy in rats: insight into molecular biology and repurposing of rosuvastatin

    Naunyn-Schmiedeberg's archives of pharmacology

  3. Rosuvastatin increases SIRT1 in rats (compared with the SHR group).

    “while the expression levels of Bcl-2 and SIRT1 were remarkably lower than those in the Rosuvastatin group (p<0.05)”

    Animalscompared with the SHR groupmyocardium

    Effect of Rosuvastatin on Myocardial Apoptosis in HypertensiveRats Through SIRT1/NF-κB Signaling Pathway

    Cellular and molecular biology (Noisy-le-Grand, France)

More on SIRT1

Extracellular matrix remodeling

downin cells1downin humans1

2 studies
  1. Rosuvastatin inhibits extracellular matrix remodeling in humans.

    “Post-treatment comparisons between groups showed that the intensive group had significantly lower levels of NT-proBNP, Galectin-3, and MMP-9 compared to the control group (P < 0.05), and significantly higher TIMP-4 levels (P < 0.05).”

    Human trial8 weeksn = 105

    Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI

    Frontiers in cardiovascular medicine

  2. Rosuvastatin inhibits extracellular matrix remodeling in humans (STEMI undergoing PCI) (P < 0.05).

    “Markers of ventricular remodeling also improved in the intensive group, with lower levels of N-terminal pro-B-type natriuretic peptide (NT-proBNP), galectin-3, and matrix metalloproteinase-9 (MMP-9)”

    Human trialSTEMI undergoing PCIheart20 mg/day vs 10 mg/day8 weeksn = 100

    Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI

    Frontiers in cardiovascular medicine

  3. Rosuvastatin inhibits extracellular matrix remodeling in response to TNF-α stimulation.

    “In vitro experiments demonstrate that rosuvastatin promotes matrix anabolism and suppresses catabolism in response to TNF-α stimulation.”

    Cellsin response to TNF-α stimulation

    Rosuvastatin suppresses TNF-α-induced matrix catabolism, pyroptosis and senescence via the HMGB1/NF-κB signaling pathway in nucleus pulposus cells

    Acta biochimica et biophysica Sinica

More on Extracellular matrix remodeling

IL-6

no changein humans1downin rats1

2 studies
  1. Rosuvastatin showed no clear effect on IL-6 in humans (head-to-head comparison with atorvastatin) (MD: -0.82).

    “We observed no significant differences for IL-6 (n = 484; MD: - 0.82; 95% CI: - 3.02 to 1.38)”

    Reviewhead-to-head comparison with atorvastatinn = 484

    Comparative effects of atorvastatin and rosuvastatin on inflammatory biomarkers: a systematic review and meta-analysis of randomized head-to-head trials

    BMC cardiovascular disorders

  2. Rosuvastatin decreases IL-6 in rats (rats fed high-fat diet, valve cusps implanted subcutaneously).

    “Statin treatment significantly attenuated bioprosthetic heart valve calcification associated with decreasing the levels of interleukin-6 and bone morphogenetic protein 2.”

    Animalsrats fed high-fat diet, valve cusps implanted subcutaneouslybioprosthetic valve cuspn = 20

    Rosuvastatin attenuates bioprosthetic heart valve calcification

    The Journal of thoracic and cardiovascular surgery

More on IL-6

Cellular senescence

downin cells2

2 studies
  1. Rosuvastatin decreases cellular senescence in bone marrow-derived macrophages.

    “Restoring lipid homeostasis with rosuvastatin enhanced lipophagy, recovered ABCA1/ABCG1-mediated cholesterol export, attenuated macrophage senescence and inflammatory activation and improved efferocytosis.”

    Cellsin bone marrow-derived macrophages

    Macrophage Lipid Homeostasis Drives IVDD via a Senescence-Dependent Impairment of Efferocytosis

    Cell proliferation

  2. Rosuvastatin inhibits cellular senescence in cells (induced by TNF-α).

    “In addition, rosuvastatin inhibits cell pyroptosis and senescence induced by TNF-α.”

    Cellsinduced by TNF-α

    Rosuvastatin suppresses TNF-α-induced matrix catabolism, pyroptosis and senescence via the HMGB1/NF-κB signaling pathway in nucleus pulposus cells

    Acta biochimica et biophysica Sinica

More on Cellular senescence

Adverse reactions

downin humans1no changein humans1

2 studies
  1. Rosuvastatin showed no clear effect on adverse reactions in humans (unstable angina pectoris).

    “No statistical difference was observed in the incidence of adverse reactions between the two groups after treatment (P>0.05).”

    Human trialunstable angina pectorisoral10 mg/day vs 5 mg/dayn = 106

    Effect of various doses of rosuvastatin in the treatment of elderly patients with unstable angina pectoris

    American journal of translational research

  2. Rosuvastatin is linked with lower adverse reactions in humans.

    “The incidence of adverse reactions such as loss of appetite, headache, dizziness, fatigue, constipation, etc. in patients in the rosuvastatin group was lower than that in the atorvastatin group, p < 0.05.”

    Humanscompared with atorvastatin in elderly patients with coronary artery disease and hyperlipidemian = 216

    Effects of rosuvastatin and atorvastatin treatment on ET-1, ADMA, and safety efficacy in elderly patients with coronary heart disease combined with hyperlipidemia

    Open life sciences

Left ventricular ejection fraction

upin humans2

2 studies
  1. Rosuvastatin increases left ventricular ejection fraction in humans.

    “Intergroup comparisons after treatment revealed that the intensive group had significantly lower LVESD and LVESV values (P < 0.05), and significantly higher LVEF and stroke volume compared to the control group (P < 0.05).”

    Human trial8 weeksn = 105

    Effects of intensive rosuvastatin on ventricular remodeling and cardiac function in elderly patients with STEMI undergoing PCI

    Frontiers in cardiovascular medicine

  2. Rosuvastatin improves left ventricular ejection fraction in humans (coronary heart disease).

    “After treatment, the observation group scored higher in the LVEF level and lower in the WMSI score than the control group (both P<0.05).”

    Human trialcoronary heart disease20 daysn = 100

    Effects of rosuvastatin combined with clopidogrel bisulfate on blood lipids, cardiac function and inflammatory factor levels in elderly patients with coronary heart disease

    American journal of translational research

Hospitalization time

downin humans2

2 studies
  1. Rosuvastatin decreases hospitalization time in humans (elective operations under general anesthesia) (13.8 ± 2.5 vs 14.2 ± 2.8, P = 0.03).

    “Rosuvastatin decreased the hospitalization time (13.8 ± 2.5 vs 14.2 ± 2.8, P = 0.03) and hospitalization expenses (9.3 ± 2.5 vs 9.8 ± 2.9, P = 0.007).”

    Human trialelective operations under general anesthesia40 mg/dn = 821

    Effects of perioperative rosuvastatin on postoperative delirium in elderly patients: A randomized, double-blind, and placebo-controlled trial

    World journal of clinical cases

  2. Rosuvastatin decreases hospitalization time in humans (elective general anesthesia operation) (13.8±2.5 vs 14.2±2.8 days, P=0.03).

    “Rosuvastatin can decrease the hospitalization time (13.8±2.5 vs 14.2±2.8, P=0.03) and hospitalization expenses (9.3±2.5 vs 9.8±2.9, P=0.007).”

    Human trialelective general anesthesia operation40 mg/day

    Effects of Perioperative Rosuvastatin for Postoperative Delirium After Elderly General Anesthesia Patients: A Randomized, Double-Blind, and Placebo-Controlled Trial

    Research SquarePreprint

Endoglin

downin humans1

1 study
  1. Rosuvastatin decreases endoglin in postmenopausal women with dyslipidemia.

    “statistically significant decreases in the plasma concentrations of the endothelial dysfunction markers endocan and endoglin were recorded in both the atorvastatin (Wilcoxon test, p < 0.001) and rosuvastatin (Wilcoxon test, p < 0.001) groups”

    Human trialin postmenopausal women with dyslipidemiamedian 12 (IQR 8–12) weeksn = 64

    The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study

    Biomedicines

  2. Rosuvastatin is linked with lower endoglin in humans (primary cardiovascular prevention).

    “Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”

    Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales

    The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study

    Biomedicines

More on Endoglin

Endocan

downin humans1

1 study
  1. Rosuvastatin decreases endocan in postmenopausal women with dyslipidemia.

    “statistically significant decreases in the plasma concentrations of the endothelial dysfunction markers endocan and endoglin were recorded in both the atorvastatin (Wilcoxon test, p < 0.001) and rosuvastatin (Wilcoxon test, p < 0.001) groups”

    Human trialin postmenopausal women with dyslipidemiamedian 12 (IQR 8–12) weeksn = 64

    The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study

    Biomedicines

  2. Rosuvastatin is linked with lower endocan in humans (primary cardiovascular prevention).

    “Atorvastatin and rosuvastatin therapies significantly decreased plasma concentrations of both endocan and endoglin”

    Humansprimary cardiovascular preventionplasmaup to 16 weeksfemales

    The Influence of Statin Therapy on Markers of Endothelial Dysfunction, Endocan and Endoglin, in Postmenopausal Women-A Prospective Study

    Biomedicines

More on Endocan

All 97

What is rosuvastatin linked with?

26

Studies link rosuvastatin with 26 measures, among them major adverse cardiovascular events, rhabdomyolysis and dementia.

Major adverse cardiovascular events

upin humans1downin humans1RR 1.21

2 studies
  1. Rosuvastatin is associated with major adverse cardiovascular events in humans (ACS and multivessel coronary disease; compared with atorvastatin) (RR 1.21, 95% CI 0.79–1.85; P = 0.372).

    “rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79–1.85; P = 0.372)”

    HumansACS and multivessel coronary disease; compared with atorvastatin3 monthsn = 277

    Guideline-directed discharge medication patterns and post-discharge outcomes in older patients with acute coronary syndrome and multivessel coronary disease: A real-world observational study

    PloS one

  2. Rosuvastatin is associated with major adverse cardiovascular events in humans (HR 0.84, 95% CI 0.76–0.93; 624 versus 769 events).

    “rosuvastatin was associated with a lower major adverse cardiovascular events rate than atorvastatin (624 versus 769 events; hazard ratio [HR], 0.84 [95% CI, 0.76-0.93]).”

    HumansPatients with cancer receiving tyrosine kinase inhibitors; comparison with atorvastatin; time-averaged association because proportional hazards were violatedDay 30 to up to 3 years

    Association of Non-Cytochrome P450 3A4-Metabolized Statins Versus Atorvastatin With Major Adverse Cardiovascular Events in Patients With Cancer Receiving Tyrosine Kinase Inhibitors: A Propensity Score-Matched Target Trial Emulation

    Journal of the American Heart Association

Rhabdomyolysis

upin humans2

2 studies
  1. Rosuvastatin is associated with rhabdomyolysis in humans (polypharmacy; adverse reaction classified as probable).

    “We present a probable case of rosuvastatin-associated rhabdomyolysis causing stage 3 acute kidney injury requiring hemodialysis in an 87-year-old woman with polypharmacy”

    Humanspolypharmacy; adverse reaction classified as probable20 mg/day20 daysfemales

    Severe Rosuvastatin-Associated Rhabdomyolysis and Dialysis-Requiring Acute Kidney Injury in an Octogenarian Patient: A Case Report

    The American journal of case reports

  2. Rosuvastatin is associated with rhabdomyolysis in humans During concomitant ticagrelor therapy after percutaneous coronary intervention.

    “We present a case of severe rhabdomyolysis and AKI following initiation of high-intensity rosuvastatin therapy after percutaneous coronary intervention.”

    HumansDuring concomitant ticagrelor therapy after percutaneous coronary intervention40 mg once dailyOne monthfemales

    Severe Rhabdomyolysis and Acute Kidney Injury Following Rosuvastatin Reinitiation During Ticagrelor Therapy: A Case Report and Literature Review

    Cureus

More on Rhabdomyolysis

Dementia

downin humans2HR 0.82

2 studies
  1. Rosuvastatin lowers the risk of dementia in APOE ε4 allele carriers.

    “Rosuvastatin medication significantly alleviated the cognitive impairment progression and the risks of dementia in patients with APOE ε4 allele.”

    Human trialin APOE ε4 allele carriers

    Telmisartan and Rosuvastatin Synergistically Ameliorate Dementia and Cognitive Impairment in Older Hypertensive Patients With Apolipoprotein E Genotype

    Frontiers in aging neuroscience

  2. Rosuvastatin is linked with a lower risk of dementia in humans (propensity-matched comparison with non-users) (adjusted HR 0.82 (95% CI 0.78-0.87)).

    “Among seven commonly prescribed statins, rosuvastatin was associated with the greatest preventive effect on dementia incidence, with an adjusted HR of 0.82 (95% CI = 0.78-0.87).”

    Humanspropensity-matched comparison with non-usersn = 264,036

    Impact of Statin Use on Dementia Incidence in Elderly Men and Women with Ischemic Heart Disease

    Biomedicines

More on Dementia

Minimum fibrous-cap thickness

upin humans1

1 study
  1. Rosuvastatin is associated with minimum fibrous-cap thickness in humans (ST-segment elevation myocardial infarction) (93.98 to 117.26 μm).

    “Minimum fibrous-cap thickness increased from 93.98 to 117.26 μm (p = 0.027)”

    HumansST-segment elevation myocardial infarctionnonculprit coronary vesselshigh-intensityn = 33

    Effect of High-Intensity Statin Therapy on Coronary Plaque Composition Assessed by Machine Learning-Based Optical Coherence Tomography Analysis

    The American journal of cardiology

Vascular dementia

downin humans1HR 0.7

1 study
  1. Rosuvastatin is associated with vascular dementia in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.70, 95% CI 0.65–0.76; incidence 0.4% vs 0.6%; ARD -0.20%, 95% CI -0.23 to -0.16).

    “rosuvastatin use was associated with significantly lower risks of incident dementia including Alzheimer dementia, and vascular dementia compared with atorvastatin.”

    Humanstype 2 diabetes; compared with atorvastatin users

    Comparative Dementia Outcomes of Rosuvastatin and Atorvastatin in Adults with Type 2 Diabetes

    AHA Scientific Sessions 2026 abstract

More on Vascular dementia

Alzheimer's disease

downin humans1HR 0.78

1 study
  1. Rosuvastatin is associated with Alzheimer's disease in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.78, 95% CI 0.72–0.83; incidence 0.5% vs 0.6%; ARD -0.18%, 95% CI -0.22 to -0.15).

    “Rosuvastatin use was also associated with lower risks of Alzheimer dementia”

    Humanstype 2 diabetes; compared with atorvastatin users

    Comparative Dementia Outcomes of Rosuvastatin and Atorvastatin in Adults with Type 2 Diabetes

    AHA Scientific Sessions 2026 abstract

More on Alzheimer's disease

Incident dementia

downin humans1HR 0.77

1 study
  1. Rosuvastatin is associated with incident dementia in humans (type 2 diabetes; compared with atorvastatin users) (HR 0.77, 95% CI 0.74–0.80; incidence 1.6% vs 2.2%; ARD -0.65%, 95% CI -0.72 to -0.58).

    “Compared with atorvastatin users, rosuvastatin users had a lower incidence of dementia”

    Humanstype 2 diabetes; compared with atorvastatin users

    Comparative Dementia Outcomes of Rosuvastatin and Atorvastatin in Adults with Type 2 Diabetes

    AHA Scientific Sessions 2026 abstract

More on Incident dementia

Hyperglycemic event reporting

upin humans1

1 study
  1. Rosuvastatin is associated with hyperglycemic event reporting in humans (FAERS pharmacovigilance analysis in patients without diabetes) (Reporting odds ratio 2.44; 95% CI 2.31–2.58).

    “rosuvastatin (ROR: 2.44; 95% CI: 2.31-2.58)”

    HumansFAERS pharmacovigilance analysis in patients without diabetes

    Risk of hyperglycemia with different statins by type and dose: a network meta-analysis and real-world pharmacovigilance study

    Frontiers in pharmacology

Acute kidney injury

upin humans1

1 study
  1. Rosuvastatin is associated with acute kidney injury in humans During concomitant ticagrelor therapy after percutaneous coronary intervention.

    “We present a case of severe rhabdomyolysis and AKI following initiation of high-intensity rosuvastatin therapy after percutaneous coronary intervention.”

    HumansDuring concomitant ticagrelor therapy after percutaneous coronary interventionkidney40 mg once dailyOne monthfemales

    Severe Rhabdomyolysis and Acute Kidney Injury Following Rosuvastatin Reinitiation During Ticagrelor Therapy: A Case Report and Literature Review

    Cureus

More on Acute kidney injury

Type 2 diabetes

upin humans1HR 1.07

1 study
  1. Rosuvastatin is linked with a higher risk of type 2 diabetes in patients with established ASCVD on moderate-intensity statin therapy (adjusted HR 1.07, 95% CI 1.01-1.14).

    “rosuvastatin (adjusted HR 1.07, 95% CI 1.01-1.14), pravastatin (HR 1.19, 95% CI 1.02-1.38), and simvastatin (HR 1.15, 95% CI 1.06-1.20) were associated with higher NODM risk compared with atorvastatin”

    Humansin patients with established ASCVD on moderate-intensity statin therapy

    Risk of new-onset diabetes across individual statins in secondary prevention: results from the Korean national health insurance service cohort

    Frontiers in cardiovascular medicine

More on Type 2 diabetes

Atrial fibrillation

downin humans1

1 study
  1. Rosuvastatin lowers the risk of atrial fibrillation in humans (8% versus 24%; p = 0.001).

    “Postoperative atrial fibrillation (AF) occurred less frequently in the loaded group (8% versus 24%, p = 0.001).”

    Human trialPostoperative incidence in chronic statin users undergoing off-pump coronary artery bypass grafting; loading versus no loading40 mg once

    Impact of Preoperative Statin Augmentation on Myocardial Injury Assessed by Biomarkers and Strain Parameters in Off-Pump Coronary Artery Bypass Grafting

    Cureus

More on Atrial fibrillation

Falls

downin humans1HR 0.532

1 study
  1. Rosuvastatin lowers the risk of falls in humans (hypertensive patients) (HR 0.532, 95% CI 0.408-0.694).

    “0.532 (95% CI 0.408-0.694), respectively, in the rosuvastatin group compared with placebo group.”

    Human trialhypertensive patientsaverage 72 monthsn = 943

    Amelioration of gait and balance disorders by rosuvastatin is associated with changes in cerebrovascular reactivity in older patients with hypertensive treatment

    Hypertension research : official journal of the Japanese Society of Hypertension

Balance impairment

downin humans1HR 0.542

1 study
  1. Rosuvastatin lowers the risk of balance impairment in humans (hypertensive patients) (HR 0.542, 95% CI 0.442-0.663).

    “The hazard ratio of incident balance impairment and falls was 0.542 [95% confidence interval (CI) 0.442-0.663] and 0.532 (95% CI 0.408-0.694), respectively, in the rosuvastatin group”

    Human trialhypertensive patientsaverage 72 monthsn = 943

    Amelioration of gait and balance disorders by rosuvastatin is associated with changes in cerebrovascular reactivity in older patients with hypertensive treatment

    Hypertension research : official journal of the Japanese Society of Hypertension

Delirium

downin humans1OR 0.522

1 study
  1. Rosuvastatin lowers the risk of delirium in humans (elective operations under general anesthesia) (OR = 0.522, 95% CI: 0.308-0.885; P < 0.05).

    “The incidence of postoperative delirium was significantly lower in the rosuvastatin group [23 (5.6%) of 410 patients] than in the placebo group”

    Human trialelective operations under general anesthesia40 mg/dn = 821

    Effects of perioperative rosuvastatin on postoperative delirium in elderly patients: A randomized, double-blind, and placebo-controlled trial

    World journal of clinical cases

More on Delirium

Cardiovascular disease

downin humans1

1 study
  1. Rosuvastatin lowers the risk of cardiovascular disease in humans (hypertension) (all p < 0.05).

    “The risks of composite cardiovascular event, myocardial infarction, coronary revascularization, heart failure, total stroke, ischemic stroke, cardiovascular death, and all-cause death were significantly lower in the rosuvastatin group”

    Human trialhypertension83.5 monthsn = 1,244

    Attenuating the Variability of Lipids Is Beneficial for the Hypertension Management to Reduce the Cardiovascular Morbidity and Mortality in Older Adults

    Frontiers in cardiovascular medicine

More on Cardiovascular disease

All 26

What acts on rosuvastatin?

1

Studies name beta-lactams as acting on rosuvastatin.

Beta-lactams

downin humans1

1 study
  1. Beta-lactams are linked with rosuvastatin in humans (patients with CHD on statin therapy).

    “concomitant β-lactam use impairs rosuvastatin efficacy in patients with CHD”

    Humanspatients with CHD on statin therapy

    Role of the Gut Microbiome in Modulating Interactions Between β-Lactam Antibiotics and Statins in Coronary Heart Disease

    Journal of cardiovascular pharmacology

More on Beta-lactams

Has rosuvastatin been tested in people?

88 of 492 about aging

Yes: 38 trials and 52 observational studies in people have been published, and 480 trials are registered.

Approved

  • FDA Crestor

    Aug 12, 2003Atherosclerosis, Homozygous Familial Hypercholesterolemia, Hypercholesterolemia, Hypertriglyceridemia, Primary Hypercholesterolemia, dysbetalipoproteinemia, heterozygous familial hypercholesterolemia

  • FDA Ezallor Sprinkle

    Dec 18, 2018Discontinued

Repurposing

40 of 128

Every condition in trials

  • Hyperlipidemias

    Phase 4Results posted34 trials

  • Hyperlipoproteinemia type II

    Phase 4Results posted4 trials

  • Coronary Artery Disease Progression

    Phase 4Completed2 trials

  • Prostatic neoplasm

    Phase 4Completed2 trials

  • Hyperlipoproteinemia type IV

    Phase 4Results posted1 trial

  • Hyperlipoproteinemia type V

    Phase 4Results posted1 trial

All 34

Stopped

  • NCT00651378TerminatedHypercholesterolemia

    Slow enrollment \[HIGH SCREEN FAILURE RATE\]

  • NCT00673582TerminatedAtherosclerosis

    Sponsor has withdrawn the funding

  • NCT02105623TerminatedCoronary artery disease

    Slow enrollement, Low Follow-up rate

  • NCT02740699TerminatedCardiovascular disease

    Principal Investigator resigned and closed program

  • NCT01975194TerminatedStroke

    loss of research personnel

  • NCT02968160TerminatedMetabolic syndrome

    Due to poor enrollment rate

All 13

Who is developing rosuvastatin?

3 companies: Organon, Merck Sharp & Dohme and AstraZeneca.

Companies
  • OrganonPhase 4hypercholesterolemia, atherosclerosis
  • Merck Sharp & DohmePhase 3hyperlipidemia
  • AstraZenecaPhase 3hypercholesterolemia, high cholesterol

Trial sponsors

Funding

1 grant since 2026

São Paulo Research Foundation

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    A human study reports lower plasma endoglin and endocan with rosuvastatin in women receiving primary cardiovascular prevention for up to 16 weeks. A review reports reduced C-reactive protein after outlier exclusion, but no TNF-alpha or IL-6 difference versus atorvastatin.

  2. Summary written from the findings.

Latest

Dec 2025: 7Jan 2026: 23Feb 2026: 18Mar 2026: 8Apr 2026: 4May 2026: 3Jun 2026: 1Jul 2026: 5Aug 2026: 10Sep 2026: 7Oct 2026: 18Nov 2026: 16120 papers in 12 months

See all 200 papers on rosuvastatin